Education
About Us
Working with TipRanks
Follow Us
Spectral Medical (EDTXF)
OTHER OTC:EDTXF
EDTXF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.30 - $0.65
Previous CloseN/A
Volume5.25K
Average Volume (3M)10.70K
Market Cap
$170.53M
Enterprise Value$253.11M
Total Cash (Recent Filing)$1.67M
Total Debt (Recent Filing)C$15.28M
Price to Earnings (P/E)―
Beta0.18
Next Earnings
Aug 08, 2025EPS EstimateN/A
Last Dividend Ex-Date
Dec 19, 2011Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding285,519,680
10 Day Avg. Volume18,263
30 Day Avg. Volume10,695
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)-6.18
Price to Sales (P/S)0.00
P/FCF Ratio-26.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$0.73Price Target Upside21.67% Upside
Rating ConsensusHold
Number of Analyst Covering0
Spectral Medical News
PremiumCompany Announcements
Spectral Medical Files Base Shelf Prospectus for Financial Flexibility
PremiumCompany Announcements
Spectral Medical Inc. Secures Shareholder Approval for Key Resolutions
PremiumCompany Announcements
Spectral Medical Advances Toward PMX Approval
PremiumCompany Announcements
Spectral Medical Completes Enrollment for Phase 3 Tigris TrialPremiumCompany Announcements
Spectral Medical Nears Completion of Key Clinical Trial for Sepsis TreatmentOptions Prices
Currently, No data available
---
Ownership Overview
0.64% Insiders
<0.01% Other Institutional Investors
99.35% Public Companies and
Individual Investors
EDTXF FAQ
What was Spectral Medical’s price range in the past 12 months?
Spectral Medical lowest stock price was $0.30 and its highest was $0.65 in the past 12 months.
What is Spectral Medical’s market cap?
Spectral Medical’s market cap is $170.53M.
When is Spectral Medical’s upcoming earnings report date?
Spectral Medical’s upcoming earnings report date is Aug 08, 2025 which is in 18 days.
How were Spectral Medical’s earnings last quarter?
Spectral Medical released its earnings results on May 09, 2025. The company reported -$0.029 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.029.
Is Spectral Medical overvalued?
According to Wall Street analysts Spectral Medical’s price is currently Undervalued.
Does Spectral Medical pay dividends?
Spectral Medical pays a Notavailable dividend of $0.12 which represents an annual dividend yield of N/A. See more information on Spectral Medical dividends here
What is Spectral Medical’s EPS estimate?
Spectral Medical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Spectral Medical have?
Spectral Medical has 285,519,680 shares outstanding.
What happened to Spectral Medical’s price movement after its last earnings report?
Spectral Medical reported an EPS of -$0.029 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Spectral Medical?
Currently, no hedge funds are holding shares in EDTXF
Company Description
Spectral Medical
Spectral Medical Inc., together with its subsidiaries, focuses on the development and commercialization of products for the treatment of septic shock and renal disease in North America. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies; and develops platform for renal replacement therapy. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.
Technical Analysis
Arch Biopartners
―
Medicenna Therapeutics Corp
―
Eastwood Bio-Medical Canada
―
Medexus Pharmaceuticals Inc
―
Profound Medical
―